Tumour suppressor gene signature predicts early progression in metastatic hormone-sensitive metastatic prostate cancer (mHSPC) patients

被引：0

作者：

Garcia De Herreros, M. ^{[1
]}

Jimenez Blasco, N. ^{[2
]}

Reig Torras, O. ^{[1
]}

Ferrer Mileo, L. ^{[1
]}

Aversa, C. ^{[1
]}

Garcia-Esteve, S. ^{[2
]}

Rodriguez-Carunchio, L. ^{[3
]}

Trias Puigsureda, I. ^{[3
]}

Padrosa, J. ^{[1
]}

Fernandez Manas, L. ^{[1
]}

Marin, M. ^{[2
]}

Font Pous, A. ^{[4
]}

Rodriguez-Vida, A. ^{[5
]}

Climent Duran, M. A. ^{[6
]}

Cros Costa, S. ^{[7
]}

Chirivella Gonzalez, I. ^{[8
]}

Figols Gorina, M. ^{[9
]}

Mellado Gonzalez, B. ^{[1
]}

机构：

[1] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain

[2] IDIBAPS Fundacio Recerca Clin Barcelona, Translat Genom & Targeted Therapeut Solid Tumors, Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain

[3] Hosp Clin Barcelona, Dept Pathol, Barcelona, Spain

[4] Hosp Badalona Germans Trias & Pujol, Dept Oncol, ICO Inst Catala Oncol Badalona, Barcelona, Spain

[5] Hosp del Mar Parc Salut Mar, Dept Med Oncol, Barcelona, Spain

[6] IVO Fdn Inst Valenciano Oncol, Med Oncol, Valencia, Spain

[7] Hosp Gen Granollers, Dept Med Oncol, Granollers, Spain

[8] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain

[9] Xarxa Assistencial Univ Manresa, Hosp St Joan Deu Althaia, Med Oncol, Manresa, Spain

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.1726

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1645P

引用

页码：S992 / S992

页数：1

共 50 条

[21] Rezvilutamide for metastatic hormone-sensitive prostate cancer
Singh, Kirti
Mandal, Swarnendu
Nayak, Prasant
Das, Manoj
Tripathy, Sambit
LANCET ONCOLOGY, 2022, 23 (11): : E490 - E490
[22] Treatment of metastatic hormone-sensitive prostate cancer
Rane, Jayant K.
Chowdhury, Amani
Kinnaird, William
Marks, Gillian
Davda, Reena
TRENDS IN UROLOGY & MENS HEALTH, 2021, 12 (06) : 7 - 10
[23] Docetaxel for hormone-sensitive metastatic prostate cancer
Baker, Holly
LANCET ONCOLOGY, 2015, 16 (09): : E432 - E432
[24] Management of Metastatic Hormone-Sensitive Prostate Cancer
Brandon Bernard
Christopher J. Sweeney
Current Urology Reports, 2015, 16
[25] Management of Hormone-Sensitive Metastatic Prostate Cancer
Agarwal, Neeraj
Hussain, Maha
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2013, 27 (06) : 1221 - +
[26] Update on Metastatic Hormone-Sensitive Prostate Cancer
Chi, Kim N.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (05) : 277 - 280
[27] Efficacy and tolerability of docetaxel chemotherapy in 'real-world' patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Maw, May Tun Hla
Malik, Laeeq
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 127 - 127
[28] Triplet Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Hindie, Elif
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (22) : 3873 - 3875
[29] Cytoreductive radical prostatectomy (cRP) in the management of patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC).
Heidenreich, Axel
Rieger, Constantin
Kastner, Lucas
Seelemeyer, Felix
Pfister, David
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[30] Radiographic progression in the absence of prostate-specific antigen (PSA) progression in patients with metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analysis of ARCHES.
Armstrong, Andrew J.
Mottet, Nicolas
Iguchi, Taro
Szmulewitz, Russell Zelig
Holzbeierlein, Jeffrey
Villers, Arnauld
Alcaraz, Antonio
Alekseev, Boris
Shore, Neal D.
Gomez-Veiga, Francisco
Rosbrook, Brad
Zohren, Fabian
Lee, Ho-Jin
Haas, Gabriel P.
Stenzl, Arnulf
Azad, Arun
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →